SLC5A5与THRB双变异致先天性甲减伴甲状腺激素抵抗
本文报告一名3岁女孩,新生儿期因SLC5A5纯合致病变异诊断为先天性甲减,左甲状腺素治疗需高剂量才能正常化TSH并出现高游离甲状腺素水平,无甲亢表现。基因测序发现同时存在THRB杂合致病变异,导致甲状腺激素抵抗β型。这是首例SLC5A5与THRB变异共存致先天性甲减和RTH-β的报道。
要点
- 先天性甲减患者左甲状腺素需求异常增高且TSH难以正常化时,应警惕甲状腺激素抵抗。
- THRB致病变异可导致RTH-β,表现为高甲状腺激素水平而无甲亢症状。
- 对疑似垂体抵抗的先天性甲减患者应进行基因检测以明确诊断。
核心结论
- 首次报告SLC5A5与THRB致病变异共存导致先天性甲减和甲状腺激素抵抗β型。
研究设计与样本
- 病例报告,收集先证者及其家族的临床、遗传和生化数据。
主要发现
- 3岁女孩新生儿期因SLC5A5纯合致病变异c.470del p.(Asn157Thrfs*3)诊断为先天性甲减。
- 左甲状腺素需显著高剂量才能正常化TSH,导致高游离甲状腺素水平,无甲亢表现。
- 测序发现THRB杂合致病变异c.947G>A p.(Arg316His)。
临床怎么用
- 先天性甲减患者若左甲状腺素需求异常增高且TSH难以正常化,应怀疑甲状腺激素抵抗并考虑THRB基因检测。
局限性
- 单例病例报告,结论外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Pituitary resistance to thyroid hormone (PRTH) is often seen in congenital hypothyroidism (CH), presenting as elevated thyrotropin (TSH) values despite (high-)normal thyroid hormone (TH) values achieved by levothyroxine treatment. In this study, we describe a girl with CH who was referred because of difficulties interpreting thyroid function tests. She was thought to have PRTH associated with CH, but genetic studies discovered a pathogenic variant in THRB, causing resistance to TH (RTH-β). Methods: Clinical, genetic, and biochemical data of the proband's family were collected. Results: The 3-year-old girl was diagnosed with CH due to a homozygous pathogenic c.470del p.(Asn157Thrfs*3) SLC5A5 variant in the neonatal period. She needed a notably high levothyroxine dose to normalize TSH, leading to high free thyroxine levels. There were no signs of hyperthyroidism. Sequencing identified a heterozygous pathogenic c.947G>A p.(Arg316His) THRB variant. Conclusions: To our knowledge, this is the first report of concomitant SLC5A5 and THRB variants causing CH and RTH-β.
引用
- Lauffer P, Bikker H, Garrelfs MR, et al. Defective Levothyroxine Response in a Patient with Dyshormonogenic Congenital Hypothyroidism Caused by a Concurrent Pathogenic Variant in Thyroid Hormone Receptor-β. Thyroid. 2021. PMID: 34382419. doi:10.1089/thy.2021.0204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。